Positive News Coverage Somewhat Unlikely to Affect Phibro Animal Health (PAHC) Stock Price

Media headlines about Phibro Animal Health (NASDAQ:PAHC) have trended positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Phibro Animal Health earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.5909057487142 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several brokerages have recently issued reports on PAHC. Piper Jaffray Companies set a $41.00 price objective on Phibro Animal Health and gave the company a “buy” rating in a report on Friday, October 6th. Zacks Investment Research cut Phibro Animal Health from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. BidaskClub raised Phibro Animal Health from a “strong sell” rating to a “sell” rating in a report on Saturday, January 6th. Finally, ValuEngine cut Phibro Animal Health from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $38.25.

Phibro Animal Health (PAHC) opened at $35.70 on Tuesday. The stock has a market capitalization of $1,430.00, a PE ratio of 21.00, a PEG ratio of 4.17 and a beta of 1.27. The company has a quick ratio of 1.85, a current ratio of 3.26 and a debt-to-equity ratio of 1.91. Phibro Animal Health has a fifty-two week low of $26.10 and a fifty-two week high of $40.25.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.01. Phibro Animal Health had a return on equity of 42.75% and a net margin of 8.87%. The firm had revenue of $193.40 million during the quarter, compared to analyst estimates of $189.89 million. During the same quarter in the previous year, the business earned $0.36 EPS. Phibro Animal Health’s revenue for the quarter was up 2.9% compared to the same quarter last year. sell-side analysts expect that Phibro Animal Health will post 1.57 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 27th. Investors of record on Wednesday, December 6th were paid a $0.10 dividend. The ex-dividend date of this dividend was Tuesday, December 5th. This represents a $0.40 annualized dividend and a dividend yield of 1.12%. Phibro Animal Health’s dividend payout ratio is presently 23.53%.

ILLEGAL ACTIVITY WARNING: This report was first reported by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://weekherald.com/2018/01/16/positive-news-coverage-somewhat-unlikely-to-affect-phibro-animal-health-pahc-stock-price.html.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Insider Buying and Selling by Quarter for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply